Shigematsu Takaaki, Yamaguchi Yu, Watanabe Takeo, Tsujimoto Kazutaka, Sato Fuminori, Yamada Tetsuya, Tsujino Motoyoshi
Fraternity Memorial Hospital, Department of Diabetology and Metabolism, Japan.
Tokyo Metropolitan Tama Medical Center, Department of Endocrinology and Metabolism, Japan.
Intern Med. 2025 Jun 1;64(11):1691-1695. doi: 10.2169/internalmedicine.5053-24. Epub 2025 Mar 22.
A 31-year-old Japanese man was admitted with a slight fever and epigastric pain. He had received his third Moderna Coronavirus disease 2019 (COVID-19) vaccine dose (Spikevax, mRNA-1273) 16 days before his visit. His serum amylase level was elevated, and computed tomography found pancreatic enlargement. Acute pancreatitis was diagnosed, and the patient was treated with fasting and intravenous fluids. However, on day 3 of hospitalization, his blood glucose level had increased to 320 mg/dL. His serum and urinary C-peptide were remarkably low (≤0.03 ng/mL and ≤0.6 μg/day, respectively). Finally, fulminant type 1 diabetes mellitus caused by the COVID-19 mRNA vaccine was diagnosed.
一名31岁的日本男子因低热和上腹部疼痛入院。他在就诊前16天接种了第三剂2019冠状病毒病（COVID-19）莫德纳疫苗（Spikevax，mRNA-1273）。他的血清淀粉酶水平升高，计算机断层扫描发现胰腺肿大。诊断为急性胰腺炎，患者接受禁食和静脉补液治疗。然而，住院第3天，他的血糖水平升至320mg/dL。他的血清和尿C肽显著降低（分别≤0.03ng/mL和≤0.6μg/天）。最终，诊断为由COVID-19 mRNA疫苗引起的暴发性1型糖尿病。
